During the past decade, Instituto do Cancer Arnaldo Vieira de Carvalho conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto do Cancer Arnaldo Vieira de Carvalho" #1 sponsor was "Janssen Research & Development, LLC" with 2 trials, followed by "Eli Lilly and Company" with 1 trials sponsored, "Genentech, Inc." with 1 trials sponsored, "Hoffmann-La Roche" with 1 trials sponsored and "Instituto Nacional de Cancer, Brazil" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto do Cancer Arnaldo Vieira de Carvalho" #1 collaborator was "Canadian Cancer Trials Group" with 1 trials as a collaborator, "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Instituto do Cancer Arnaldo Vieira de Carvalho" are "Non Small Cell Lung Carcinoma" (2 trials), "Abiraterone Acetate" (1 trials), "Androgens" (1 trials), "Antineoplastic Agents" (1 trials) and "Antineoplastic Agents, Hormonal" (1 trials). Many other conditions were trialed in "Instituto do Cancer Arnaldo Vieira de Carvalho" in a lesser frequency.

Most popular intervention types in "Instituto do Cancer Arnaldo Vieira de Carvalho" are "Drug" (9 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (2 trials), "Docetaxel" (2 trials), "Pertuzumab" (2 trials), "Abemaciclib" (1 trials) and "Abiraterone" (1 trials). Other intervention names were less common.

The vast majority of trials in "Instituto do Cancer Arnaldo Vieira de Carvalho" are 5 trials for "All" genders, 3 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Instituto do Cancer Arnaldo Vieira de Carvalho". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Instituto do Cancer Arnaldo Vieira de Carvalho, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto do Cancer Arnaldo Vieira de Carvalho, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".